Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage
- 1 November 2011
- journal article
- Published by Elsevier in Microvascular Research
- Vol. 82 (3) , 346-350
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- University of Nebraska Medical Center
This publication has 26 references indexed in Scilit:
- Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in ratsEuropean Journal of Pharmacology, 2011
- Simvastatin Inhibits Leukocyte Accumulation and Vascular Permeability in the Retinas of Rats with Streptozotocin-Induced DiabetesThe American Journal of Pathology, 2004
- VEGF164Is Proinflammatory in the Diabetic RetinaInvestigative Ophthalmology & Visual Science, 2003
- VEGF-initiated blood-retinal barrier breakdown in early diabetes.2001
- VEGF increases retinal vascular ICAM-1 expression in vivo.1999
- Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells.1998
- Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat.Diabetes, 1998
- Growth factors and diabetic retinopathy.1997
- Assessment of blood-retinal barrier integrity.1995
- Molecular size of retinal vascular leakage determined by FITC-dextran angiography in patients with posterior uveitisEye, 1991